ProfileGDS5678 / 1434951_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 83% 83% 78% 81% 86% 82% 83% 81% 85% 85% 82% 81% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3261185
GSM967853U87-EV human glioblastoma xenograft - Control 26.1809683
GSM967854U87-EV human glioblastoma xenograft - Control 36.0434283
GSM967855U87-EV human glioblastoma xenograft - Control 45.4720278
GSM967856U87-EV human glioblastoma xenograft - Control 55.7747381
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3430586
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7999182
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0561483
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8226181
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3347585
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2971685
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0411282
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.750981
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1260683